Abstract:e12565 Background: HER2-low could be found in some patients with triple-negative breast cancer (TNBC). However, its potential impacts on clinical features and tumor biological characteristics in TNBC remain unclear. Methods: We enrolled 251 consecutive TNBC patients retrospectively, including 157 HER2-low (HER2 low ) and 94 HER2-negtive (HER2 neg ) patients to investigate the clinical and prognostic features. Then, we performed single-cell RNA sequencing (scRNA-seq) with another seven TNBC samples (HER2 neg vs. HER2 low , 4 vs. 3) prospectively to further explore the differences of tumor biological properties between the two TNBC phenotypes. The underlying molecular distinctions were also explored and then verified in the additional TNBC samples. Results: Compared with HER2 neg TNBC, HER2 low TNBC patients exhibited malignant clinical features with larger tumor size ( P = 0.04), more lymph nodes involvement ( P = 0.02), higher histological grade of lesions ( P < 0.001), higher Ki67 status ( P < 0.01), and a worse prognosis ( P < 0.001; HR [CI 95%] = 3.44 [2.10-5.62]). Cox proportional hazards analysis showed that neoadjuvant systemic therapy, lymph nodes involvement and Ki67 levels were prognostic factors in HER2 low TNBC but not in HER2 neg TNBC patients. scRNA-seq revealed that HER2 low TNBC which showed more metabolically active and aggressive hallmarks, while HER2 neg TNBC exhibited signatures more involved in immune activities with higher expressions of immunoglobulin-related genes ( IGHG1, IGHG4, IGKC, IGLC2); this was further confirmed by immunofluorescence in clinical TNBC samples. Furthermore, HER2 low and HER2 neg TNBC exhibited distinct tumor evolutionary characteristics. Moreover, HER2 neg TNBC revealed a potentially more active immune microenvironment than HER2 low TNBC, as evidenced by positively active regulation of macrophage polarization, abundant CD8 + effector T cells, enriched diversity of T-cell receptors and higher levels of immunotherapy-targeted markers, which contributed to achieve immunotherapeutic response. Conclusions: This study suggests that HER2 low TNBC patients harbor more malignant clinical behavior and aggressive tumor biological properties than the HER2 neg phenotype. The heterogeneity of HER2 may be a non-negligible factor in the clinical management of TNBC patients. Our data provides new insights into the development of a more refined classification and tailored therapeutic strategies for TNBC patients.

Multiomics and single-cell sequencings reveal the specific biological characteristics of low Ki-67 triple-negative breast cancer

Multi-Omics and Single-Cell Sequencing Reveal the Genomic Features and Metabolic Heterogeneity of Low Ki-67 Triple-Negative Breast Cancer

Overexpression of PKMYT1 associated with poor prognosis and immune infiltration may serve as a target in triple-negative breast cancer

Integrative multi-omic profiling of triple-negative breast cancer for identifying suitable therapies

Multi-Omics Profiling Reveals Distinct Microenvironment Characterization and Suggests Immune Escape Mechanisms of Triple-Negative Breast Cancer

Heterogeneity and potential therapeutic insights for triple-negative breast cancer based on metabolic‐associated molecular subtypes and genomic mutations

Clinical and biological heterogeneity in triple-negative breast cancer and HER2-low.

Multi-omics analysis identifies therapeutic vulnerabilities in triple-negative breast cancer subtypes

Genomic characterization reveals distinct mutational landscapes and therapeutic implications between different molecular subtypes of triple-negative breast cancer

Revealing Cellular Heterogeneity and Key Regulatory Factors of Triple-Negative Breast Cancer through Single-Cell RNA Sequencing

Integrated analysis of single-cell RNA-seq and bulk RNA-seq unravels T cell-related prognostic risk model and tumor immune microenvironment modulation in triple-negative breast cancer

Integrated molecular profiling of young and elderly patients with triple-negative breast cancer indicates different biological bases and clinical management strategies

Progress and Challenges of Immunotherapy Predictive Biomarkers for Triple Negative Breast Cancer in the Era of Single-Cell Multi-Omics

Single-cell Atlas Reveals a Distinct Immune Profile Fostered by T Cell-B Cell Crosstalk in Triple Negative Breast Cancer

Quantitative Proteomics Reveals Stage-Specific Protein Regulation of Triple Negative Breast Cancer

A Retrospective View of the Triple-Negative Breast Cancer Microenvironment: Novel Markers, Interactions, and Mechanisms of Tumor-Associated Components Using Public Single-Cell RNA-Seq Datasets

A Single-Cell Immune Atlas of Triple Negative Breast Cancer Reveals Novel Immune Cell Subsets

Abstract 1763A: Single-cell RNA-sequencing Reveals the Immune Contexture of Triple-Negative Breast Cancer Tumors

New Insights into the Prognostic Value of Ki-67 Labeling Index in Patients with Triple-Negative Breast Cancer.

Proteome-centric cross-omics characterization and integrated network analyses of triple-negative breast cancer

Multiomics of HER2-low Triple-Negative Breast Cancer Identifies a Receptor Tyrosine Kinase–relevant Subgroup with Therapeutic Prospects